Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 18Sarcoma 7Genitourinary 6Other solid neoplasm 3Gastrointestinal 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Dermatologic 2CNS 2Plasma cell 1Gynecologic 1

Conditions

Solid Tumor 1Sarcoma, Synovial 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hepatic Impairment 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
tazemetostat × Other solid neoplasm × 1 year × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health-Upstate

Phase 2 Terminated
20 enrolled
Other solid neoplasm

Solid Tumor

NCT02875548 2025-11-04

TRuST

Ipsen

Phase 1/2 Completed
58 enrolled
LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡